Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NVV9

UPID:
THAP1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9NVV9; A6NCB6; D3DSY5; H9KV49; Q53FQ1; Q6IA99

BACKGROUND:
The THAP domain-containing protein 1 is integral to regulating endothelial cell proliferation and cell-cycle progression by specifically binding to DNA sequences and influencing the expression of pivotal genes. Its involvement in a complex that regulates transcriptional activity underscores its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given its association with Dystonia 6, torsion, a disease marked by abnormal postures due to involuntary muscle contractions, the study of THAP domain-containing protein 1 offers promising avenues for therapeutic intervention, highlighting the importance of genetic research in uncovering treatment pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.